NCT07221253 2026-03-17
AB02
AstraZeneca
Phase 3 Recruiting
Clinical Trials
8 trialsNCT02616640 2024-09-19
A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Celgene
Phase 1 Completed
NCT03323398 2024-07-31
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
ModernaTX, Inc.
Phase 1/2 Terminated
NCT02369874 2021-02-10
EAGLE
AstraZeneca
Phase 3 Completed
NCT02207530 2020-09-29
Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
AstraZeneca
Phase 2 Completed
NCT02319044 2020-09-29
Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck
AstraZeneca
Phase 2 Completed
NCT02221960 2019-03-13
A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
MedImmune LLC
Phase 1 Completed
NCT03000452 2018-10-16
FUSION-MM-005
Celgene
Phase 2 Completed